Adipose Derived Stem Cell Therapy Market Revenue Growth Predicted by 2018-2026

Adipose derived stem cells (ADSCs) are stem cells
derived from adipocytes, and can differentiate into variety of cell
types. ADSCs have multipotency similar to bone marrow mesenchymal
stem cells, thus ADSCs substitute for bone marrow as a source of stem
cells. Numerous manual and automatic stem cell separation procedures
are adopted in order to separate adipose stem cells (ASCs) from
adipose tissue. Flow cytometry can also be used to isolate ADSCs from
other stem cells within a cell solution.
Get Exclusive Sample Report at:
https://www.coherentmarketinsights.com/insight/request-sample/2357
Adipose derived stem cells are gaining appeal as a
new cell source in regenerative medicine therapies as it can be
differentiated into a variety of different cell lineages. These stem
cells also have anti-apoptotic, anti-inflammatory, pro-angiogenic,
immunomodulatory, and anti-scarring properties, which enhances its
effectiveness.
Adipose Derived Stem Cell Therapy Market
Drivers
High effectiveness of adipose derived stem cell
therapy in various medical and biotechnology research fields coupled
with growing research and development activities by various research
organizations is expected to boost the adoption of adipose-derived
stem cell therapy in the market during the forecast period. Adipose
derived stem cells (ADSCs) have various applications in medical and
biomedical science field such as treatment of diabetes; regeneration
of tissues partially in osteogenic, adipogenic, chondrogenic, and
cardiovascular areas of medicine; bone regeneration; fat
reconstruction; and myocardial and cardiovascular regeneration; among
others.
For instance, in November 2018, a peer-reviewed
case study conducted using a stem cell processed by Celltex
Therapeutics Corporation, showed the improvement in disease findings
following systemic administration of autologous adipose derived
mesenchymal stem cells (MSCs).
Adipose Derived Stem Cell Therapy Market
Regional Analysis
North America is expected to hold a dominant
position in the global adipose derived stem cell therapy market and
account the largest market share during the forecast period, owing to
high presence of key players in the region, which are engaged in
research & development activities and implementing in-organic
growth strategies such as acquisition and collaboration to increase
its market presence.
For instance, in December 2017, Mesoblast Limited
made exclusive license agreement with TiGenix NV, through which
Mesoblast granted TiGenix an exclusive access to certain of its
patents to support global commercialization of Cx601, adipose derived
mesenchymal stem cell product, for the local treatment of fistulae.
Adipose Derived Stem Cell Therapy Market
Restraint
High cost associated with stem cell processing,
need of skilled professional for managing, preserving, and scale-up
of stem cell lines are the limiting factors, which are expected to
restrain the growth of the adipose derived stem cell therapy market
during the forecast period.
For instance, Bioinformant— a research firm
engaged in stem cell research— released a data on November 2018, on
cost of stem cell therapy and various key factors impacting the cost
of stem cell therapy including types of stem cells used within
procedure, number of treatment, and the site of the clinic. The study
findings reveal the cost of stem cell therapy ranges between US$
5,000-8,000 per patient, in some cases it may rise as much as US$
25,000 or more depending on the complexity of the procedure.
Ask For Discount Before Purchasing This Business
Report @
https://www.coherentmarketinsights.com/insight/request-discount/2357
Adipose Derived Stem Cell Therapy Market Key
Players
Key players operating in the global adipose
derived stem cell therapy market include BioRestorative Therapies,
Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori
Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells
Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher
Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen,
Inc., and Lonza Group, among others.
Adipose Derived Stem Cell Therapy Market
Taxonomy:
The global adipose derived stem cell therapy
market is segmented on the basis of cell type, product type,
application, end user, and region.
By Cell Type
Allogeneic Stem Cells
Autologous Stem Cells
By Product Type
Cell lines
Culture Media
By Application
Therapeutic Application
Research Application
By End User
Cell & Tissue Banks
Biotechnology & Pharmaceutical
organizations
Research & Academic Organizations
By Region
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
About Coherent Market Insights
Coherent Market Insights is a prominent market
research and consulting firm offering action-ready syndicated
research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment